Tenofovir Disoproxil Market Report 2026

The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.76 billion in 2025 to $3.96 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high global hiv prevalence, expansion of antiretroviral therapy programs, inclusion in first-line treatment guidelines, growth in hepatitis b diagnosis, donor-funded antiviral access programs.

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for chronic viral management, expansion of generic antiviral production, increasing healthcare access in emerging markets, growth in preventive antiviral use, sustained public health funding. Major trends in the forecast period include rising demand for antiviral combination therapies, increased use in hiv and hepatitis b management, growing adoption of fixed-dose combinations, expansion of long-term antiviral treatment, increased focus on viral suppression strategies.

The increasing incidence of hepatitis B is anticipated to drive the expansion of the tenofovir disoproxil market in the coming years. Hepatitis B is a viral infection that targets the liver and can result in both short-term and long-term illness, spreading through exposure to infected blood or bodily fluids. The rise in hepatitis B cases is attributed to factors such as mother-to-child transmission, unsafe healthcare procedures, insufficient vaccination coverage, and the continued presence of chronic infections within affected populations. Tenofovir disoproxil is widely used in managing chronic hepatitis B by inhibiting viral replication and minimizing liver damage. For example, in March 2023, a report released by the Centers for Disease Control and Prevention, a US-based public health agency, estimated that between 580,000 and 2.4 million individuals in the United States are living with hepatitis B, with nearly two-thirds potentially unaware of their infection. As a result, the rising prevalence of hepatitis B is contributing to the growth of the tenofovir disoproxil market.

The increasing healthcare expenditure is anticipated to drive the expansion of the tenofovir disoproxil market in the coming years. Healthcare expenditure represents the overall financial resources allocated to medical goods and services aimed at maintaining and improving population health. This spending is rising largely because an aging population demands more frequent medical attention and long-term healthcare services. Greater healthcare expenditure facilitates the adoption of tenofovir disoproxil by expanding access to antiviral treatments, enhancing diagnosis and treatment rates, and strengthening healthcare systems’ ability to manage chronic conditions such as hepatitis B and HIV. For example, in April 2025, data from the Office for National Statistics, a UK-based government body, indicated that between 2023 and 2024, total healthcare spending grew by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. Consequently, rising healthcare expenditure is expected to support the growth of the tenofovir disoproxil market.

Major companies operating in the tenofovir disoproxil space are prioritizing wider availability through internationally quality-certified formulations, including WHO-prequalified tablets, to serve HIV and hepatitis B patients worldwide. A WHO-prequalified tenofovir disoproxil fumarate tablet complies with stringent global benchmarks for quality, safety, and effectiveness, supporting expanded distribution in resource-constrained regions. For example, in August 2024, Shijiazhuang Lonzeal Pharmaceuticals Co., Ltd., a China-based pharmaceutical manufacturer, obtained WHO prequalification for its 300 mg tenofovir disoproxil fumarate film-coated tablet (Product code HP030), demonstrating bioequivalence, adherence to GMP standards, and suitability for HIV therapy. As a result, the availability of globally certified, high-quality supply is contributing to the expansion of the tenofovir disoproxil market.

Major companies operating in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Mylan N.V., Qilu Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Hetero Drugs Limited, Laurus Labs Limited, Zydus Lifesciences Ltd., Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd., Arene Lifesciences, Aurisco Pharmaceutical Co. Ltd., Sinoway Industrial Co. Ltd.

North America was the largest region in the tenofovir disoproxil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tenofovir disoproxil market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted tenofovir disoproxil supply by increasing the cost of imported APIs used in tablet and powder formulation manufacturing. These effects are most pronounced in Africa and Asia Pacific, where reliance on cross border sourcing for antiviral inputs remains high. Rising tariff related expenses have placed pressure on production costs, pricing structures, and procurement planning for HIV treatment programs. This has influenced supply availability across public health systems and hospital pharmacies. Positively, tariffs are encouraging domestic antiviral drug manufacturing, expanded local API production, and stronger regional supply chain resilience over the long term.

The tenofovir disoproxil market research report is one of a series of new reports that provides tenofovir disoproxil market statistics, including tenofovir disoproxil industry global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tenofovir disoproxil is a drug prescribed for the management of HIV-1 infection and long-term hepatitis B. As a prodrug of tenofovir, it is converted into its active form within the body, where it inhibits viral replication. It belongs to the nucleotide reverse transcriptase inhibitor (NRTI) category, which interferes with a critical enzyme required for virus reproduction.

The primary forms of tenofovir disoproxil include tablets and powders. A tablet is a solid pharmaceutical dosage form compressed into a compact, easy-to-ingest shape, intended to dissolve within the digestive tract to release the active substance either immediately or over time. The distribution pathways consist of online pharmacies, retail drugstores, and wholesalers or distributors, and its applications are found in hospitals and clinics.

The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.